conduct
phase
clinic
trial
experiment
live
attenu
recombin
human
metapneumoviru
hmpv
vaccin
rhmpvpa
sequenti
adult
hmpvseroposit
children
hmpvseroneg
children
target
popul
vaccin
rhmpvpa
appropri
restrict
replic
adult
hmpvseroposit
children
overattenu
hmpvseroneg
children
human
metapneumoviru
hmpv
first
report
although
serolog
studi
confirm
global
circul
human
least
year
like
respiratori
syncyti
viru
rsv
hmpv
caus
upper
respiratori
ill
otiti
media
lower
respiratori
ill
lri
includ
bronchiol
croup
pneumonia
exacerb
asthma
infant
young
children
although
mean
age
hmpvinfect
infant
typic
older
rsvinfect
infant
unit
state
hmpv
associ
pediatr
hospit
respiratori
ill
medic
attend
lri
children
hmpv
second
third
lead
caus
viral
lri
children
also
caus
sever
diseas
prematur
infant
elderli
immunocompromis
peopl
hmpv
vaccin
could
reduc
global
burden
lri
infant
children
live
attenu
intranas
administ
hmpv
vaccin
would
potenti
advantag
induc
full
spectrum
local
system
immun
respons
replic
upper
respiratori
tract
infant
even
presenc
matern
deriv
antibodi
previous
develop
live
attenu
hmpv
design
rhmpvpa
chimer
viru
express
p
protein
relat
avian
metapneumoviru
ampv
subtyp
c
protein
hmpv
experiment
vaccin
candid
replic
effici
vitro
attenu
highli
immunogen
hamster
nonhuman
primat
nhp
report
evalu
phase
clinic
trial
adult
hmpvseroposit
children
hmpvseroneg
children
rhmpvpa
deriv
complementari
dna
cdna
previous
describ
clinic
trial
materi
manufactur
qualifi
vero
cell
charl
river
laboratori
malvern
pa
store
dilut
site
use
qualifi
leibovitz
medium
medium
also
use
placebo
trial
conduct
center
immun
research
john
hopkin
bloomberg
school
public
health
march
decemb
year
vaccin
evalu
sequenti
adult
screen
hmpv
serostatu
prove
hmpvseroposit
hmpvseroposit
children
age
month
hmpvseroneg
children
age
month
studi
adult
open
label
subject
receiv
vaccin
studi
children
random
doubleblind
placebocontrol
subject
assign
randomli
receiv
vaccin
placebo
administ
nose
drop
ml
per
nostril
dose
vaccin
plaqueform
unit
pfu
adult
hmpvseroposit
children
pfu
dose
evalu
sequenti
hmpvseroneg
children
written
inform
consent
obtain
studi
particip
adult
parent
guardian
studi
particip
children
enrol
conduct
phase
clinic
trial
experiment
live
attenu
recombin
human
metapneumoviru
hmpv
vaccin
rhmpvpa
sequenti
adult
hmpvseroposit
children
hmpvseroneg
children
target
popul
vaccin
rhmpvpa
appropri
restrict
replic
adult
hmpvseroposit
children
overattenu
hmpvseroneg
children
human
metapneumoviru
hmpv
first
report
although
serolog
studi
confirm
global
circul
human
least
year
like
respiratori
syncyti
viru
rsv
hmpv
caus
upper
respiratori
ill
otiti
media
lower
respiratori
ill
lri
includ
bronchiol
croup
pneumonia
exacerb
asthma
infant
young
children
although
mean
age
hmpvinfect
infant
typic
older
rsvinfect
infant
unit
state
hmpv
associ
pediatr
hospit
respiratori
ill
medic
attend
lri
children
hmpv
second
third
lead
caus
viral
lri
children
also
caus
sever
diseas
prematur
infant
elderli
immunocompromis
peopl
hmpv
vaccin
could
reduc
global
burden
lri
infant
children
live
attenu
intranas
administ
hmpv
vaccin
would
potenti
advantag
induc
full
spectrum
local
system
immun
respons
replic
upper
respiratori
tract
infant
even
presenc
matern
deriv
antibodi
previous
develop
live
attenu
hmpv
design
rhmpvpa
chimer
viru
express
p
protein
relat
avian
metapneumoviru
ampv
subtyp
c
protein
hmpv
experiment
vaccin
candid
replic
effici
vitro
attenu
highli
immunogen
hamster
nonhuman
primat
nhp
report
evalu
phase
clinic
trial
adult
hmpvseroposit
children
hmpvseroneg
children
rhmpvpa
deriv
complementari
dna
cdna
previous
describ
clinic
trial
materi
manufactur
qualifi
vero
cell
charl
river
laboratori
malvern
pa
store
dilut
site
use
qualifi
leibovitz
medium
medium
also
use
placebo
trial
conduct
center
immun
research
john
hopkin
bloomberg
school
public
health
march
decemb
year
vaccin
evalu
sequenti
adult
screen
hmpv
serostatu
prove
hmpvseroposit
hmpvseroposit
children
age
month
hmpvseroneg
children
age
month
studi
adult
open
label
subject
receiv
vaccin
studi
children
random
doubleblind
placebocontrol
subject
assign
randomli
receiv
vaccin
placebo
administ
nose
drop
ml
per
nostril
dose
vaccin
plaqueform
unit
pfu
adult
hmpvseroposit
children
pfu
dose
evalu
sequenti
hmpvseroneg
children
written
inform
consent
obtain
studi
particip
adult
parent
guardian
studi
particip
children
enrol
studi
conduct
accord
standard
good
clinic
practic
defin
intern
confer
harmon
clinicaltrialsgov
identifi
clinic
protocol
consent
form
investig
brochur
review
approv
western
institut
review
board
nation
institut
allergi
infecti
diseas
niaid
regulatori
complianc
human
subject
protect
branch
clinic
data
review
center
immun
research
niaid
investig
data
safeti
monitor
board
niaid
divis
clinic
research
adult
hmpvseroposit
children
clinic
assess
nasal
wash
nw
perform
studi
day
nw
perform
inocul
day
day
inocul
ill
data
advers
reactogen
event
collect
day
addit
physic
examin
perform
nw
obtain
event
lower
respiratori
tract
ill
lri
seroneg
children
clinic
assess
nw
perform
day
day
ill
data
seroneg
children
obtain
day
physic
examin
perform
addit
nw
obtain
event
lri
titer
vaccin
viru
nw
fluid
determin
describ
fever
upper
respiratori
ill
rhinorrhea
pharyng
cough
lri
otiti
media
defin
describ
previous
ill
occur
nw
fluid
specimen
test
adventiti
agent
realtim
reversetranscript
polymeras
chain
reaction
rrtpcr
fasttrack
diagnost
luxembourg
sera
obtain
particip
inocul
measur
antibodi
hmpv
adult
seroposit
children
specimen
obtain
month
inocul
seroneg
children
specimen
obtain
month
inocul
nw
perform
nw
fluid
snapfrozen
store
describ
previous
viral
cultur
quantif
perform
describ
previous
lower
limit
detect
log
pfuml
shed
vaccin
viru
also
quantifi
realtim
quantit
pcr
describ
previous
lower
limit
detect
log
copiesml
test
sera
antibodi
hmpv
use
plaquereduct
neutral
assay
enzymelink
immunosorb
assay
quantit
immunoglobulin
g
igg
antibodi
hmpv
fusion
f
protein
infect
vaccin
viru
defin
isol
vaccin
viru
andor
rise
antibodi
titer
mean
peak
titer
vaccin
viru
shed
log
pfuml
copi
number
per
ml
calcul
infect
vaccin
recipi
plaquereduct
neutral
enzymelink
immunosorb
assay
reciproc
titer
transform
log
valu
calcul
mean
log
titer
rate
ill
among
vaccin
recipi
placebo
recipi
compar
fisher
exact
test
rhmpvpa
evalu
adult
dose
pfu
vaccin
viru
detect
subject
neutral
hmpv
f
igg
antibodi
respons
four
subject
respiratori
system
ill
judg
tabl
limit
detect
vaccin
viru
cultur
log
pfuml
limit
detect
realtim
quantit
polymeras
chain
reaction
rtqpcr
log
unrel
vaccin
rhinorrhea
pharyng
cough
muscl
sore
hoars
associ
shed
human
coronaviru
subject
nasal
congest
rhinorrhea
pharyng
cough
hoars
wheez
headach
fatigu
associ
detect
rsv
type
subject
transient
mild
chill
myalgia
studi
day
subject
emesi
associ
detect
coronaviru
subject
find
reveal
rhmpvpa
highli
attenu
adult
next
pfu
dose
evalu
hmpvseroposit
children
vaccin
recipi
placebo
recipi
vaccin
viru
detect
subject
neutral
antibodi
respons
detect
hmpv
f
igg
antibodi
respons
detect
asymptomat
vaccin
recipi
tabl
follow
mild
ill
occur
judg
unrel
vaccin
rhinorrhea
day
vaccin
recipi
rhinoviru
detect
day
rhinorrhea
day
placebo
recipi
rhinoviru
enteroviru
detect
day
epistaxi
nw
vaccin
recipi
placebo
recipi
episod
emesi
vaccin
recipi
emesi
rectal
temperatur
placebo
recipi
rhmpvpa
evalu
next
dose
pfu
hmpvseroneg
children
vaccin
recipi
placebo
recipi
shed
vaccin
viru
detect
antibodi
respons
detect
vaccin
recipi
tabl
ill
occur
vaccin
recipi
rhinorrhea
rhinorrhea
cough
rhinorrhea
otiti
media
hoars
rhinoviru
detect
subject
ill
also
occur
placebo
recipi
rash
emesi
nasal
congest
rhinorrhea
otiti
media
nasal
congest
alon
rhinoviru
detect
nw
fluid
child
nasal
congest
rhinorrhea
otiti
media
coronaviru
detect
child
nasal
congest
alon
pfu
dose
minim
infecti
pfu
dose
evalu
next
hmpvseroneg
children
vaccin
recipi
placebo
recipi
shed
vaccin
viru
detect
cultur
detect
rrtqpcr
vaccin
recipi
day
day
vaccin
recipi
asymptomat
neutral
antibodi
respons
detect
vaccin
recipi
hmpv
f
igg
respons
detect
vaccin
recipi
includ
neutral
antibodi
respons
shed
viru
recipi
pfu
dose
infect
vaccin
viru
observ
respiratori
febril
ill
vaccin
recipi
placebo
recipi
fever
vaccin
recipi
parainfluenza
viru
type
infect
detect
placebo
recipi
associ
urinari
tract
infect
fever
rhinorrhea
cough
vaccin
recipi
parainfluenza
viru
type
bocaviru
detect
rhinorrhea
placebo
recipi
adenoviru
bocaviru
detect
rate
ill
differ
significantli
treatment
group
tabl
howev
basi
low
infect
rate
appar
overattenu
rhmpvpa
studi
termin
effect
hmpv
vaccin
could
prevent
substanti
number
respiratori
tract
ill
young
children
knowledg
rhmpvpa
remain
hmpv
vaccin
evalu
clinic
trial
although
rhmpvpa
immunogen
protect
hmpv
challeng
nhp
experiment
vaccin
overattenu
ie
insuffici
infecti
immunogen
hmpvseroneg
children
thu
although
preclin
studi
identifi
appropri
vaccin
candid
care
stepwis
assess
clinic
trial
essenti
result
studi
also
highlight
need
placebocontrol
trial
assess
adventiti
viral
infect
young
children
respiratori
ill
occur
frequent
popul
futur
effort
develop
live
attenu
hmpv
vaccin
warrant
data
rhmpvpa
provid
preclin
benchmark
help
identifi
vaccin
candid
less
attenu
candid
might
includ
exampl
rhmpvna
bear
ampv
n
gene
rather
ampv
p
gene
shown
less
attenu
rhmpvpa
upper
lower
respiratori
tract
nhp
hmpv
delet
sh
g
gene
shown
less
attenu
upper
lower
respiratori
tract
nhp
rhmpvpa
hmpv
bear
point
mutat
design
compar
mutat
rsv
yet
evalu
nhp
